Camlin Fine Sciences Limited
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
What Camlin files
- Others88
- Investor Meet28
- Important23
- Updates14
- Board Meeting11
- PPTs8
Camlin Fine Sciences Limited has appointed Mr. Atul Pradhan as an Additional Non-Executive Independent Director for a five-year term, subject to shareholder approval. The company has also approved the notice for a postal ballot to facilitate this appointment. Mr. Pradhan is an IICA-certified Independent Director and corporate advisor with extensive...
Camlin Fine Sciences (CFS) reported Q1FY27 revenues of ₹519.9 Cr (up 28% YoY) but low 4% margins, primarily due to high raw material costs and a one-quarter lag in price pass-through. Specialty Ingredients saw 6.35% EBITDA, while Aroma had negative EBITDA from cautious Ethyl Vanillin ramp-up and low capacity utilization....
The audio recording of Camlin Fine Sciences Limited's conference call on the un-audited financial results (consolidated and standalone) for the quarter ended June 30, 2026, is now available on the company's website. Management was represented by Mr. Ashish Dandekar, Mr. Nirmal Momaya, and Mr. Santosh Parab.
Camlin Fine Sciences (CFS) achieved its highest-ever quarterly revenue in Q1FY27 at ₹519.9 Cr, marking a 27.5% YoY jump. Despite this, consolidated EBITDA stood at ₹17.6 Cr (3.4% margin), and the company posted a Net Loss of ₹31.8 Cr. Gross margins were impacted by higher raw material prices and limited...
Camlin Fine Sciences' board approved Q1 results. Consolidated Revenue was ₹519.88 Cr, with a net loss of ₹31.71 Cr. The company increased its stake in Vinpai S.A. to 95.41% and adopted new segment reporting.